Article

Simeprevir Responsible for Deaths in Japanese Hepatitis C Patients

A spike in the blood bilirubin levels resulting in hepatic dysfunction and/or renal impairment was determined as the cause of death.

Sovriad (simeprevir sodium) was launched in Japan in December 2013. Of an estimated 18,900 patients taking the medication for hepatitis C infection, 3 deaths have been reported till October 2014. Hepatic and or renal impairement resulting from a significant increase in blood bilirubin levels was identified as the cause of death. The Pharmaceutical and Medical Devices Agency in Japan subsequently issued a "Dear Healthcare Professional Letter" and also asked Janssen to update the Warnings Subsection in the Precautions Section within the label.

Link to the letter issued by PMDA: http://bit.ly/1waEwBf

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Dan Nardi
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo